Lipocine receives complete response letter for tlando from u.s. fda

Lipocine receives complete response letter for tlando™ from u.s. fda.lipocine inc - crl identified one deficiency stating efficacy trial did not meet three secondary endpoints for maximal testosterone concentrations.lipocine inc - crl does not identify any specific issues relating to chemistry, manufacturing and controls ("cmc") of tlando.lipocine inc - continue to actively enroll in ongoing lpcn 1144 lift phase 2 clinical study.lipocine inc - "disappointed by fda's decision".lipocine inc - intend to request a meeting with fda to discuss a potential path forward for approval of tlando.
LPCN Ratings Summary
LPCN Quant Ranking